{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:59:38Z","timestamp":1794614378963,"version":"4.9.1"},"reference-count":139,"publisher":"Oxford University Press (OUP)","issue":"42","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,7]]},"DOI":"10.1093\/eurheartj\/ehaf190","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T06:17:02Z","timestamp":1756448222000},"page":"4359-4378","source":"Crossref","is-referenced-by-count":766,"title":["2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3178-9131","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Mach","sequence":"first","affiliation":[{"name":"(Switzerland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos C","family":"Koskinas","sequence":"additional","affiliation":[{"name":"(Switzerland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6870-9962","authenticated-orcid":false,"given":"Jeanine E","family":"Roeters van Lennep","sequence":"additional","affiliation":[{"name":"(Netherlands)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6441-3339","authenticated-orcid":false,"given":"Lale","family":"Tokg\u00f6zo\u011flu","sequence":"additional","affiliation":[{"name":"(T\u00fcrkiye)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-2459","authenticated-orcid":false,"given":"Lina","family":"Badimon","sequence":"additional","affiliation":[{"name":"(Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4856-7420","authenticated-orcid":false,"given":"Colin","family":"Baigent","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1701-595X","authenticated-orcid":false,"given":"Marianne","family":"Benn","sequence":"additional","affiliation":[{"name":"(Denmark)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8313-7050","authenticated-orcid":false,"given":"Christoph J","family":"Binder","sequence":"additional","affiliation":[{"name":"(Austria)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-2094","authenticated-orcid":false,"given":"Alberico L","family":"Catapano","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1660-1623","authenticated-orcid":false,"given":"Guy G","family":"De Backer","sequence":"additional","affiliation":[{"name":"(Belgium)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9841-2737","authenticated-orcid":false,"given":"Victoria","family":"Delgado","sequence":"additional","affiliation":[{"name":"(Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-4925","authenticated-orcid":false,"given":"Natalia","family":"Fabin","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A","family":"Ference","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0979-4674","authenticated-orcid":false,"given":"Ian M","family":"Graham","sequence":"additional","affiliation":[{"name":"(Ireland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[{"name":"(Germany)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2620-9323","authenticated-orcid":false,"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[{"name":"(Germany)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0951-1304","authenticated-orcid":false,"given":"Borislava","family":"Mihaylova","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-7220","authenticated-orcid":false,"given":"B\u00f8rge Gr\u00f8nne","family":"Nordestgaard","sequence":"additional","affiliation":[{"name":"(Denmark)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0245-4690","authenticated-orcid":false,"given":"Dimitrios J","family":"Richter","sequence":"additional","affiliation":[{"name":"(Greece)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0691-3359","authenticated-orcid":false,"given":"Marc S","family":"Sabatine","sequence":"additional","affiliation":[{"name":"(United States of America)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ESC\/EAS Scientific Document Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Eugen","family":"Mueller","sequence":"additional","affiliation":[{"name":"(Switzerland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[{"name":"(Austria)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Abreu","sequence":"additional","affiliation":[{"name":"(Portugal)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Adamo","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleman","family":"Aktaa","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folkert W","family":"Asselbergs","sequence":"additional","affiliation":[{"name":"(Netherlands)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Baldini","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Brida","sequence":"additional","affiliation":[{"name":"(Croatia)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Brodmann","sequence":"additional","affiliation":[{"name":"(Austria)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edina","family":"Cenko","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Dagres","sequence":"additional","affiliation":[{"name":"(Germany)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn","family":"Dopheide","sequence":"additional","affiliation":[{"name":"(Switzerland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Ebenbichler","sequence":"additional","affiliation":[{"name":"(Austria)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Gandjbakhch","sequence":"additional","affiliation":[{"name":"(France)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana A","family":"Gorog","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Gouni-Berthold","sequence":"additional","affiliation":[{"name":"(Germany)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigina","family":"Guasti","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Heidecker","sequence":"additional","affiliation":[{"name":"(Germany)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Ibanez","sequence":"additional","affiliation":[{"name":"(Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"James","sequence":"additional","affiliation":[{"name":"(Sweden)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Juni","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ka\u0142u\u017cna-Oleksy","sequence":"additional","affiliation":[{"name":"(Poland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin A","family":"Krychtiuk","sequence":"additional","affiliation":[{"name":"(Austria)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Lorusso","sequence":"additional","affiliation":[{"name":"(Netherlands)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[{"name":"(Switzerland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Moelgaard","sequence":"additional","affiliation":[{"name":"(Denmark)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Morais","sequence":"additional","affiliation":[{"name":"(Portugal)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lis","family":"Neubeck","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E","family":"Nissen","sequence":"additional","affiliation":[{"name":"(United States of America)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Osto","sequence":"additional","affiliation":[{"name":"(Austria\/Switzerland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus G","family":"Parhofer","sequence":"additional","affiliation":[{"name":"(Germany)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leopoldo Perez","family":"De Isla","sequence":"additional","affiliation":[{"name":"(Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pesce","sequence":"additional","affiliation":[{"name":"(Italy\/Saudi Arabia)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaneta","family":"Petrulioniene","sequence":"additional","affiliation":[{"name":"(Lithuania)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Prescott","sequence":"additional","affiliation":[{"name":"(Denmark)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Rietzschel","sequence":"additional","affiliation":[{"name":"(Belgium)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Fernando","family":"Rodriguez Palomares","sequence":"additional","affiliation":[{"name":"(Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Rossello","sequence":"additional","affiliation":[{"name":"(Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sannino","sequence":"additional","affiliation":[{"name":"(Germany)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Grete","family":"Semb","sequence":"additional","affiliation":[{"name":"(Norway)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta M","family":"Siller-Matula","sequence":"additional","affiliation":[{"name":"(Austria)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thenral","family":"Socrates","sequence":"additional","affiliation":[{"name":"(Switzerland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix C","family":"Tanner","sequence":"additional","affiliation":[{"name":"(Switzerland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Wojta","sequence":"additional","affiliation":[{"name":"(Austria)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zambon","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Zeppenfeld","sequence":"additional","affiliation":[{"name":"(Netherlands)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Laredj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamlet","family":"Hayrapetyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Stefan","family":"Speidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuad","family":"Samadov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"van de Borne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zumreta","family":"Kusljugic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Postadzhiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hera","family":"Heracleous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Ostadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn Lund","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Seleem","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margus","family":"Viigimaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Juonala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Boccara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archil","family":"Chukhrukidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Weing\u00e4rtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Marketou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Gabor","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel F","family":"Sigurdsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaakov","family":"Henkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savina","family":"Nodari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makhabbat","family":"Bekbossynova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranvera","family":"Ibrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkin","family":"Mirrakhimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanda","family":"Jegere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Arnaout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Bheleel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgita","family":"Plisiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Abela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Ivanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Boskovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazzi","family":"Mbarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J G","family":"Leening","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijan","family":"Bosevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth K","family":"Vesterbekkmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Kubica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Pop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto Maria","family":"Stefanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojislav","family":"Giga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatko","family":"Fras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Fernandez-Olmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Sudano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Yassin Bani","family":"Marjeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faten","family":"Triki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffer M","family":"Degertekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Mitchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitava","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Shek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"2026080910064825200_ehaf190-B1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B2","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B3","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","author":"SCORE2 working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B4","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in Familial Chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B8","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"2026080910064825200_ehaf190-B9","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"key":"2026080910064825200_ehaf190-B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2022.10.013","article-title":"Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements on lipids and inflammatory biomarkers","volume":"81","author":"Laffin","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B11","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1161\/CIRCULATIONAHA.120.052209","article-title":"Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized, controlled trial","volume":"143","author":"Kalstad","year":"2021","journal-title":"Circulation"},{"key":"2026080910064825200_ehaf190-B12","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B13","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists Collaboration","year":"2010","journal-title":"Lancet"},{"key":"2026080910064825200_ehaf190-B14","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Prospective Studies Collaboration","year":"2007","journal-title":"Lancet"},{"key":"2026080910064825200_ehaf190-B15","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.jacc.2023.09.814","article-title":"Determinants of progression and regression of subclinical atherosclerosis over 6 years","volume":"82","author":"Mendieta","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B16","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1093\/eurheartj\/ehab604","article-title":"Effect of evolocumab on acute arterial events across all vascular territories: results from the FOURIER trial","volume":"42","author":"Oyama","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B17","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/eurjpc\/zwad318","article-title":"Validation of systematic coronary risk evaluation 2 (SCORE2) and SCORE2-older persons in the EPIC-Norfolk prospective population cohort","volume":"31","author":"van Trier","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026080910064825200_ehaf190-B19","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/ehjci\/jeae044","article-title":"Association between subclinical atherosclerosis burden and unrecognized myocardial infarction detected by cardiac magnetic resonance in middle-aged low-risk adults","volume":"25","author":"Fernandez-Friera","year":"2024","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080910064825200_ehaf190-B20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jama.2018.4242","article-title":"Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"320","author":"Lin","year":"2018","journal-title":"JAMA"},{"key":"2026080910064825200_ehaf190-B21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.atherosclerosis.2022.02.006","article-title":"Coronary artery calcium scores indicating secondary prevention level risk: findings from the CAC consortium and FOURIER trial","volume":"347","author":"Dzaye","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026080910064825200_ehaf190-B22","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1093\/eurheartj\/ehy217","article-title":"Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA)","volume":"39","author":"Budoff","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B23","doi-asserted-by":"publisher","first-page":"e010153","DOI":"10.1161\/CIRCIMAGING.119.010153","article-title":"Predictive value of coronary artery calcium score categories for coronary events versus strokes: impact of sex and race: MESA and DHS","volume":"13","author":"Mehta","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026080910064825200_ehaf190-B24","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.120.050545","article-title":"Very high coronary artery calcium (\u22651000) and association with cardiovascular disease events, non-cardiovascular disease outcomes, and mortality: results from MESA","volume":"143","author":"Peng","year":"2021","journal-title":"Circulation"},{"key":"2026080910064825200_ehaf190-B25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jcmg.2019.02.005","article-title":"Long-term all-cause and cause-specific mortality in asymptomatic patients with CAC \u22651,000: results from the CAC Consortium","volume":"13","author":"Peng","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080910064825200_ehaf190-B26","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jcmg.2015.01.025","article-title":"A 15-year warranty period for asymptomatic individuals without coronary artery calcium: a prospective follow-up of 9,715 individuals","volume":"8","author":"Valenti","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080910064825200_ehaf190-B27","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1093\/eurjpc\/zwad187","article-title":"Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2","volume":"30","author":"Hageman","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2026080910064825200_ehaf190-B28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.7326\/M22-3027","article-title":"Subclinical coronary atherosclerosis and risk for myocardial infarction in a Danish cohort: a prospective observational cohort study","volume":"176","author":"Fuchs","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026080910064825200_ehaf190-B29","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.jcmg.2018.04.015","article-title":"Effects of statins on coronary atherosclerotic plaques: the PARADIGM study","volume":"11","author":"Lee","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080910064825200_ehaf190-B30","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1001\/jamacardio.2021.3055","article-title":"Association of statin treatment with progression of coronary atherosclerotic plaque composition","volume":"6","author":"van Rosendael","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026080910064825200_ehaf190-B31","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B32","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1093\/eurheartj\/ehad260","article-title":"SCORE2-diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe","volume":"44","author":"SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B33","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/jamacardio.2022.1876","article-title":"Statin eligibility for primary prevention of cardiovascular disease according to 2021 European Prevention Guidelines compared with other international guidelines","volume":"7","author":"Mortensen","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026080910064825200_ehaf190-B34","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.jacc.2023.01.024","article-title":"Association of incident cardiovascular disease with time course and cumulative exposure to multiple risk factors","volume":"81","author":"Domanski","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B35","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jama.2019.14120","article-title":"Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease","volume":"322","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"2026080910064825200_ehaf190-B36","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.jacc.2024.06.045","article-title":"Influence of subclinical atherosclerosis burden and progression on mortality","volume":"84","author":"Fuster","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B37","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026080910064825200_ehaf190-B38","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists Collaboration","year":"2015","journal-title":"Lancet"},{"key":"2026080910064825200_ehaf190-B39","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists Collaborators","year":"2012","journal-title":"Lancet"},{"key":"2026080910064825200_ehaf190-B40","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s11883-022-01054-2","article-title":"Bempedoic acid: for whom and when","volume":"24","author":"Ruscica","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"2026080910064825200_ehaf190-B41","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"2026080910064825200_ehaf190-B42","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B43","doi-asserted-by":"publisher","first-page":"100278","DOI":"10.1016\/j.ajpc.2021.100278","article-title":"Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins","volume":"8","author":"Bays","year":"2021","journal-title":"Am J Prev Cardiol"},{"key":"2026080910064825200_ehaf190-B44","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2026080910064825200_ehaf190-B45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S2213-8587(23)00316-9","article-title":"Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR outcomes randomised trial","volume":"12","author":"Ray","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026080910064825200_ehaf190-B46","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of ACLY and cardiovascular disease","volume":"380","author":"Ference","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B47","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jacc.2024.04.048","article-title":"Comparative cardiovascular benefits of bempedoic acid and statin drugs","volume":"84","author":"Lincoff","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B48","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B49","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 Update on European Atherosclerosis Society Consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B50","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","article-title":"Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy","volume":"45","author":"Gaudet","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B51","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","article-title":"Evinacumab for pediatric patients with homozygous familial hypercholesterolemia","volume":"149","author":"Wiegman","year":"2024","journal-title":"Circulation"},{"key":"2026080910064825200_ehaf190-B52","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1161\/CIRCULATIONAHA.118.039415","article-title":"Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial","volume":"140","author":"Ouchi","year":"2019","journal-title":"Circulation"},{"key":"2026080910064825200_ehaf190-B53","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"2026080910064825200_ehaf190-B54","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"2026080910064825200_ehaf190-B55","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"2026080910064825200_ehaf190-B56","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"2026080910064825200_ehaf190-B57","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial","volume":"46","author":"Ray","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B58","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B59","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B60","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/clc.23116","article-title":"Predictors of all-cause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: results from the EPICOR registry","volume":"42","author":"Rossello","year":"2019","journal-title":"Clin Cardiol"},{"key":"2026080910064825200_ehaf190-B61","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B62","doi-asserted-by":"publisher","first-page":"e022198","DOI":"10.1161\/JAHA.121.022198","article-title":"Event rates and risk factors for recurrent cardiovascular events and mortality in a contemporary post acute coronary syndrome population representing 239 234 patients during 2005 to 2018 in the United States","volume":"11","author":"Steen","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026080910064825200_ehaf190-B63","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/eurheartj\/ehaa1011","article-title":"Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study","volume":"42","author":"Schubert","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B64","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries","volume":"285","author":"De Backer","year":"2019","journal-title":"Atherosclerosis"},{"key":"2026080910064825200_ehaf190-B65","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026080910064825200_ehaf190-B66","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B67","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B68","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.120.046320","article-title":"Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period: a placebo-controlled, randomized trial","volume":"142","author":"Leucker","year":"2020","journal-title":"Circulation"},{"key":"2026080910064825200_ehaf190-B69","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1007\/s00392-022-02147-3","article-title":"Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (\u201cJena auf Ziel\u201d)","volume":"112","author":"Makhmudova","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2026080910064825200_ehaf190-B70","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080910064825200_ehaf190-B71","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"Raber","year":"2022","journal-title":"JAMA"},{"key":"2026080910064825200_ehaf190-B72","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.120.049447","article-title":"Clinical efficacy and safety of alirocumab after acute coronary syndrome according to achieved level of low-density lipoprotein cholesterol: a propensity score-matched analysis of the ODYSSEY OUTCOMES trial","volume":"143","author":"Schwartz","year":"2021","journal-title":"Circulation"},{"key":"2026080910064825200_ehaf190-B73","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"2026080910064825200_ehaf190-B74","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/eurheartj\/ehad144","article-title":"Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial","volume":"44","author":"Schwartz","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B75","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1093\/eurheartj\/ehae576","article-title":"Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry","volume":"45","author":"Schubert","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B76","doi-asserted-by":"publisher","first-page":"e069770","DOI":"10.1136\/bmjopen-2022-069770","article-title":"Temporal trends in cardiovascular risk factors, lifestyle and secondary preventive medication for patients with myocardial infarction attending cardiac rehabilitation in Sweden 2006\u20132019: a registry-based cohort study","volume":"13","author":"Leosdottir","year":"2023","journal-title":"BMJ Open"},{"key":"2026080910064825200_ehaf190-B77","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1093\/eurheartj\/ehaa034","article-title":"Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study","volume":"41","author":"Allahyari","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B78","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society Consensus Statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B79","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B80","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","author":"Bjornson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B81","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2023.09.836","article-title":"Per-particle cardiovascular risk of lipoprotein(a) vs non-Lp(a) apolipoprotein B-containing lipoproteins","volume":"83","author":"Marston","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B82","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1093\/eurjpc\/zwaa063","article-title":"Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions","volume":"28","author":"Welsh","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026080910064825200_ehaf190-B83","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"2026080910064825200_ehaf190-B84","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B85","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B86","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk","volume":"79","author":"Mehta","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B87","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1016\/j.jacc.2022.09.021","article-title":"Equivalent impact of elevated lipoprotein(a) and familial hypercholesterolemia in patients with atherosclerotic cardiovascular disease","volume":"80","author":"Hedegaard","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B88","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/eurheartj\/ehad055","article-title":"Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein","volume":"44","author":"Thomas","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B89","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.jacc.2023.10.009","article-title":"Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, and major adverse limb events","volume":"82","author":"Thomas","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B90","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1093\/eurheartj\/ehaf209","article-title":"Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study","volume":"46","author":"Kraaijenhof","year":"2025","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B91","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","article-title":"Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the Copenhagen general population study","volume":"355","author":"Simony","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026080910064825200_ehaf190-B92","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026080910064825200_ehaf190-B93","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"2026080910064825200_ehaf190-B94","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B95","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B96","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"2026080910064825200_ehaf190-B97","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"2026080910064825200_ehaf190-B98","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"key":"2026080910064825200_ehaf190-B99","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"key":"2026080910064825200_ehaf190-B100","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran-a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"2026080910064825200_ehaf190-B101","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jacc.2023.12.031","article-title":"Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease","volume":"83","author":"Berman","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B102","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1093\/eurheartj\/ehac822","article-title":"Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality","volume":"44","author":"Wadstrom","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B103","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jacc.2022.10.019","article-title":"Elevated LDL triglycerides and atherosclerotic risk","volume":"81","author":"Balling","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B104","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1016\/j.jacc.2021.04.059","article-title":"Triglycerides and residual atherosclerotic risk","volume":"77","author":"Raposeiras-Roubin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B105","doi-asserted-by":"publisher","first-page":"CD009580","DOI":"10.1002\/14651858.CD009580.pub2","article-title":"Fibrates for secondary prevention of cardiovascular disease and stroke","volume":"2015","author":"Wang","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080910064825200_ehaf190-B106","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Group","year":"2010","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B107","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"2026080910064825200_ehaf190-B108","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","article-title":"Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial","volume":"373","author":"Rajamani","year":"2009","journal-title":"Lancet"},{"key":"2026080910064825200_ehaf190-B109","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B110","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","article-title":"2024 ESC Guidelines for the management of peripheral arterial and aortic diseases","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B111","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"Suppl J","key":"2026080910064825200_ehaf190-B112","doi-asserted-by":"publisher","first-page":"J34","DOI":"10.1093\/eurheartj\/suaa117","article-title":"Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies","volume":"22","author":"Olshansky","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"2026080910064825200_ehaf190-B113","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1161\/CIRCULATIONAHA.122.059410","article-title":"Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1beta, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy","volume":"146","author":"Ridker","year":"2022","journal-title":"Circulation"},{"key":"2026080910064825200_ehaf190-B114","author":"U.S. Food & Drug Administration"},{"key":"2026080910064825200_ehaf190-B115","doi-asserted-by":"publisher","first-page":"e034076","DOI":"10.1161\/JAHA.123.034076","article-title":"Eicosapentaenoic acid improves endothelial nitric oxide bioavailability via changes in protein expression during inflammation","volume":"13","author":"Sherratt","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026080910064825200_ehaf190-B116","doi-asserted-by":"publisher","first-page":"102450","DOI":"10.1016\/j.plefa.2022.102450","article-title":"A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes","volume":"182","author":"Sherratt","year":"2022","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2026080910064825200_ehaf190-B117","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJMc2306575","article-title":"Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia","volume":"390","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B118","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B119","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and Familial Chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B120","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B121","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"key":"2026080910064825200_ehaf190-B122","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"2026080910064825200_ehaf190-B123","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1161\/CIRCULATIONAHA.122.057443","article-title":"Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context","volume":"147","author":"Ntsekhe","year":"2023","journal-title":"Circulation"},{"key":"2026080910064825200_ehaf190-B124","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1161\/CIRCULATIONAHA.117.028975","article-title":"Cardiovascular risk prediction functions underestimate risk in HIV infection","volume":"137","author":"Triant","year":"2018","journal-title":"Circulation"},{"key":"2026080910064825200_ehaf190-B125","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/COH.0000000000000756","article-title":"Cardiovascular disease risk in women living with HIV","volume":"17","author":"Kentoffio","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"2026080910064825200_ehaf190-B126","author":"University of Liverpool"},{"key":"2026080910064825200_ehaf190-B127","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1097\/01.aids.0000247573.95880.db","article-title":"Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins","volume":"20","author":"Negredo","year":"2006","journal-title":"AIDS"},{"key":"2026080910064825200_ehaf190-B128","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1097\/QAD.0b013e32833068e3","article-title":"Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients","volume":"23","author":"Chow","year":"2009","journal-title":"AIDS"},{"key":"2026080910064825200_ehaf190-B129","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12944-015-0054-x","article-title":"Lipid lowering efficacy and safety of ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients","volume":"14","author":"Saeedi","year":"2015","journal-title":"Lipids Health Dis"},{"key":"2026080910064825200_ehaf190-B130","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.jacc.2020.03.025","article-title":"Evolocumab in HIV-infected patients with dyslipidemia: primary results of the randomized, double-blind BEIJERINCK study","volume":"75","author":"Boccara","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026080910064825200_ehaf190-B131","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","article-title":"Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults","volume":"22","author":"Hequet","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026080910064825200_ehaf190-B132","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/1074248418821721","article-title":"Effect of rosuvastatin in preventing chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized, single-blind, placebo-controlled trial","volume":"24","author":"Nabati","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026080910064825200_ehaf190-B133","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and left ventricular ejection fraction following doxorubicin treatment","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid"},{"key":"2026080910064825200_ehaf190-B134","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","article-title":"Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines","volume":"9","author":"Thavendiranathan","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026080910064825200_ehaf190-B135","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080910064825200_ehaf190-B136","doi-asserted-by":"publisher","first-page":"131219","DOI":"10.1016\/j.ijcard.2023.131219","article-title":"Statins as preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized controlled trials","volume":"391","author":"D\u2019Amario","year":"2023","journal-title":"Int J Cardiol"},{"key":"2026080910064825200_ehaf190-B137","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejim.2024.04.007","article-title":"Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: an updated meta-analysis of randomized controlled trials","volume":"126","author":"Felix","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026080910064825200_ehaf190-B138","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3945\/jn.108.095125","article-title":"Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake","volume":"139","author":"Demonty","year":"2009","journal-title":"J Nutr"},{"key":"2026080910064825200_ehaf190-B139","author":"The European Commission"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/42\/4359\/64074780\/ehaf190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/42\/4359\/64074780\/ehaf190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T14:06:55Z","timestamp":1786284415000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/42\/4359\/8234482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":139,"journal-issue":{"issue":"42","published-online":{"date-parts":[[2025,8,29]]},"published-print":{"date-parts":[[2025,11,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,7]]},"published":{"date-parts":[[2025,8,29]]}}}